Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study

Creative Commons License

Stilgenbauer S., Bosch F., Ilhan O., Kisro J., Mahe B., Mikuskova E., ...Daha Fazla

BRITISH JOURNAL OF HAEMATOLOGY, cilt.193, sa.2, ss.325-338, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 193 Sayı: 2
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1111/bjh.17326
  • Dergi Adı: BRITISH JOURNAL OF HAEMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, BIOSIS, CAB Abstracts, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.325-338
  • Anahtar Kelimeler: Obinutuzumab, chronic lymphocytic leukaemia, safety, IGHV, minimal residual disease
  • Ondokuz Mayıs Üniversitesi Adresli: Evet

Özet

The manageable toxicity profile of obinutuzumab (GA101; G) alone or with chemotherapy in first-line (1L; fit and non-fit) and relapsed/refractory (R/R) patients with chronic lymphocytic leukaemia (CLL) was established in the primary analysis of the Phase IIIb GREEN trial (Clinicaltrials.gov: NCT01905943). The final analysis (cut-off, 31 January 2019) is reported here. Patients received G (1000 mg) alone (G-mono; fit and non-fit patients) or with chemotherapy [fludarabine and cyclophosphamide (FC; fit patients); chlorambucil (non-fit patients); bendamustine (any patient)]. Study endpoints were safety (primary) and efficacy (secondary). Subgroup analyses were performed on prognostic biomarkers in 1L CLL. Overall, 630 patients received 1L and 341 received R/R CLL treatment. At the final analysis, no new safety signals were observed [Grade >= 3 adverse events (AEs): 1L 82 center dot 7%, R/R 84 center dot 5%; serious AEs: 1L 58 center dot 1%, R/R 62 center dot 5%]. Neutropenia (1L 50 center dot 5%, R/R 53 center dot 4%) and thrombocytopenia (1L 14 center dot 6%, R/R 19 center dot 1%) were the most common Grade 3-5 AEs. G-mono-, G-bendamustine and G-FC-treated patients with unmutated immunoglobulin heavy chain trended towards shorter progression-free survival. Achievement of minimal residual disease negativity was greatest in 1L patients treated with G-FC. In this final analysis of the GREEN trial, the safety profile of G was consistent with current risk management strategies. Biomarker analyses supported efficacy in the specific subgroups.